OTLK icon

Outlook Therapeutics
OTLK

Overview Fund Activity

61 hedge funds and large institutions have $8.59M invested in Outlook Therapeutics in 2024 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
61
Holders Change
-5
Holders Change %
-7.58%
% of All Funds
0.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
23
Reduced
11
Closed
19
Calls
$3.61M
Puts
$4K
Net Calls
+$3.61M
Net Calls Change
+$2.05M

Top Buyers

1
UBS Group
1
UBS Group
Switzerland
$542K
2
Fidelity Investments
2
Fidelity Investments
Massachusetts
$343K
3
RhumbLine Advisers
3
RhumbLine Advisers
Massachusetts
$355K
4
Renaissance Technologies
4
Renaissance Technologies
New York
$246K
5
GCP
5
GSA Capital Partners
United Kingdom
$190K

Top Sellers

1
GPP
1
Great Point Partners
Connecticut
$0
2
ACM
2
Altium Capital Management
New York
$0
3
TCM
3
Tang Capital Management
California
$345K
4
RA
4
Rosalind Advisors
Ontario, Canada
$0
5
SFM
5
Sphera Funds Management
Israel
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
SWA
76
SOA Wealth Advisors
New York
– -$1.6K -300 Closed
Nisa Investment Advisors
77
Nisa Investment Advisors
Missouri
– -$80 -15 Closed
FFA
78
Farther Finance Advisors
California
– -$16 -3 Closed
National Bank of Canada
79
National Bank of Canada
Quebec, Canada
– -$5 -1 Closed
1 2 3
4